The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, successfully advances the next phase of value creation with its FME Reignite strategy.

A mounting wave of recent research argues that high-volume hemodiafiltration, or Hv-HDF, may significantly improve outcomes for people with kidney failure compared to standard hemodialysis treatments.

Fresenius Medical Care AG & Co. FMS is well-positioned for growth, backed by strong profitability improvements from its FME25+ transformation program and growing momentum in value-based care, and ...

Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. This will enable Fresenius Medical Care to offer the industry ...

and innovation The Company will set the new standard of care in the U.S. with the introduction of the FME Reignite shapes the future of Fresenius Medical Care with three main elements. REIGNITE THE ...

BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second ...

"Fresenius Medical Care delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income ...

Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and ...